

# EFFECT OF PLASMODIUM VIVAX MALARIA ON LIVER FUNCTION

Gagan Deep<sup>A</sup>, Chandra Shekhar Srivastava<sup>B</sup>

<sup>A</sup> - Associate Professor, Department of General Medicine, K.D. Medical College Hospital & Research Center, Mathura

<sup>B</sup> - Associate Professor, Department of General Medicine, K.D. Medical College Hospital & Research Center, Mathura

## Medicine

Manuscript reference number  
NJMDR\_5102\_16

Article submitted on: 11 Oct. 2016  
Article accepted on: 15 Oct. 2016

### Corresponding Author

Dr Gagan Deep  
Associate Professor,  
Department of General Medicine,  
K.D. Medical College Hospital &  
Research Center,  
Mathura (U.P.)

### Abstract:

**Objective:** The present study was conducted on malaria patients with plasmodium vivax infection to see the effect on liver functions and correlation between liver enzymes (SGOT & SGPT) and bilirubin

**Material & Methods:** The study population contained 114 subjects divided into two groups, 64 malaria patients and 50 healthy control subjects of varying age groups and both sex. All biochemical parameters Total bilirubin, Direct bilirubin, Indirect bilirubin, SGOT (aspartate transaminase), SGPT (alanine transaminase) & were analyzed by semiautoanalyser. Statistical analysis was done by , science (SPSS 21) Software

**Results:** In our study we have found that (Mean  $\pm$  SD) of Total serum bilirubin in malaria patients were  $1.41 \pm 1.56$  & controls were  $0.28 \pm 0.038$ , Direct bilirubin in malarial patients were  $0.48 \pm 0.43$  & control were  $0.13 \pm 0.031$ , Indirect bilirubin in malarial patients was  $0.93 \pm 1.29$ . We observed that (Mean  $\pm$  SD) of SGOT in malaria patients was  $46.91 \pm 31.38$  & in control were  $22 \pm 5.22$ , the level of SGPT in malarial subjects were  $35.61 \pm 19.41$  & control subjects were  $16 \pm 3.12$ . We observed statistically significant increase in levels of enzymes SGOT, SGPT and bilirubin in malarial patients ( $p < 0.001$ ) as compared to controls. Both the amino transferases (AST & ALT) did not show statistically significant positive correlation with bilirubin ( $p > 0.05$ ).

**Conclusion:** Our study indicates that liver enzymes SGOT & SGPT significantly increases in malaria patients with plasmodium vivax infection as compared to control subjects therefore these enzymes may be useful in diagnosis of malaria subjects.

**Keyword:** Plasmodium vivax, Malaria, Liver function

### Introduction:

Malaria is a febrile illness caused by protozoa of the genus plasmodium, transmitted to human by the bite of infected female anopheles mosquito. There are mainly four species of Plasmodium Vivax, P. Falciparum, P. Ovale and P. Malaria. A fifth species P. Knowlesi, a zoonotic malaria parasite, is an important cause of malaria in parts of Southeast Asia, but not reported in India.<sup>1</sup> Malaria is responsible for infecting 300-500 million and 1-3 million deaths annually.<sup>2</sup> Malaria can be transmitted by three known ways;

vector transmission, blood transfusion and congenital transmission. The malaria parasite interferes with 3 major organs in the body, namely: the brain, kidney and liver.<sup>3</sup>

In India, the epidemiology of malaria is complex because of geo-economical diversity, multiethnicity and wide distribution of nine anopheline vectors transmitting three Plasmodial species: P. falciparum, P. vivax and P. malariae. Anopheles culicifacies is widely distributed and is the principal vector of rural malaria. The proportion of P. vivax and P. falciparum

varies in different parts of India. Mostly indo-gangatic plains and northern hilly states, north-western India and southern Tamil Nadu state have < 10% *p. falciparum* and rests are *p. vivax* infections. In the forested area inhabited by the ethnic tribes, the situation is reversed with *p. falciparum* proportion 30-90% whereas in the remaining areas it is between 10-30%.<sup>4,5</sup>

*P. falciparum* infection in India is a major cause of severe and complicated malaria, but with the implementation of molecular diagnosis, it has become evident that *P. vivax* mono infection could also result in multiple organ dysfunction and severe life-threatening disease, like *P. falciparum* infection.<sup>6</sup> large studies from Indonesia, Papua new guinea, Thailand and India now show a strong association between *P. vivax* infection and severe disease and death. So there is a recent changing trend of benign behavior of *P. vivax* to malignant behavior.

Malarial transmission to the human host is established by sporozoites infection to the liver. The malarial sporozoite once injected into the blood by the bite of female anopheles mosquitoes is attached to the hepatocytes through the receptor for thrombospondin and properdin. Here these sporozoites become mature to form tissue schizonts or become dormant hypnozoites. Tissue schizonts amplify the infection by producing large number of merozoites.<sup>7</sup> Merozoite infects and ruptures the liver cells in an attempt to escape back into the circulation and continues the infection. The infection of liver cells by the sporozoites form of the malarial parasite can cause organ congestion, sinusoidal blockage and cellular inflammation. These changes in hepatocytes can lead to the leakage of parenchymal (transaminases) enzymes of the liver to the circulation. Hence increase in liver enzymes AST & ALT observed in malaria infected patients also demonstrated that the serum activities of these liver enzymes increased with the increase in malarial parasite density and confirmed that the hepatic stage of the parasite's life cycle in human host is accompanied by significant perturbation in the hepatocyte's parenchyma and membrane leading to leakage of liver enzymes into the general circulation.<sup>8,9</sup> Jaundice is also one of the common manifestations of severe malaria in adults causing high mortality rate and incidence of jaundice vary from 10-45% in different regions.<sup>4</sup>

*P. vivax* infection is common in children and pregnant woman.<sup>10</sup> Pregnant women are also especially vulnerable. Susceptible groups are children and adults who have lost

or never acquired immunity. Morbidity and mortality due to malaria have remained unabated primarily as a result of the unavailability of suitable vaccines and the spread and intensification of drug resistant Plasmodium parasites. In severe *vivax* malaria, the various complications were thrombocytopenia (89%), renal (33%), hepatic (19%), cerebral (08%), metabolic acidosis (04%), and pulmonary (01%).<sup>11</sup> Thus it is rational to assess the current status of malaria related complications in order to estimate the burden among biologically risked groups, children and endemic areas.

## **Materials and methods**

The subjects included in the study were 64 clinically diagnosed patients suffering from *P. vivax* malaria of both sex and varying age groups, attending the out-patients department (OPD), emergency ward and from indoor patients, from K.D. Medical College Hospital & Research Center, Mathura (U.P.) Fifty healthy controls were selected for the study from volunteers such as paramedical staff, healthy relatives / attendants of patients. The patients comprised 38 males and 26 females. The control group comprised of 28 males and 22 females.

Patients selection criteria: Patients with the following conditions; pregnancy, renal diseases, liver diseases including cirrhosis, hepatitis, obstructive jaundice, alcoholism, cancer, metabolic bone diseases, gastrointestinal tract infection, protein energy malnutrition, diabetes, heart failure, infectious mononucleosis and magnesium / vitamin D deficiencies, were excluded from the study. This is because these conditions are associated with significant changes in serum alanine and aspartate transaminases activities. Similarly, patients on self-medication with any antimalarial drug prior to presentation were also excluded from the study. Blood samples were collected by clean veinpuncture and centrifuged. Sera was collected and analysed for serum bilirubin and enzyme activity of SGOT & SGPT using kit method by erba chem semiautoanalyzer.

## **Statistical analysis**

Statistical analysis was done, using the statistical package for social science (SPSS 21) for Windows Software. Differences in the parameters between the groups were analyzed by means of the t test. Variables were presented

as mean  $\pm$  standard deviation (S.D.). The accepted level of significance for all statistical analyses used in the study was  $P \leq 0.05$ .

## Results

Level of serum bilirubin and liver enzymes (SGOT, SGPT) were increased in the patient with malaria infection as compared to the controls and the increase was statistically highly significant ( $p < 0.001$ ). (Table-1)

**Table-1: Comparison of serum bilirubin and liver enzymes among controls and malaria patients**

Variables	Controls	Malaria Patients	P value
Total Bilirubin (mg/dl)	0.28 $\pm$ .038	1.41 $\pm$ 1.56	0.0001
Direct bilirubin (mg/dl)	0.13 $\pm$ 0.031	.48 $\pm$ 0.43	.0001
Indirect bulirubin (mg/dl)	0.15 $\pm$ 0.012	.93 $\pm$ 1.29	.0001
SGOT (IU/L)	22.31 $\pm$ 5.22	46.09 $\pm$ 31.37	.0001
SGPT (IU/L)	16.84 $\pm$ 3.12	35.62 $\pm$ 19.440	.0001

Significant increase in serum bilirubin & liver enzymes was obtained in malaria female patients as compare to the control (Table-2)

**Table-2: Comparison of serum total bilirubin and liver enzymes among female controls and female malaria patients**

Parameters	Controls	Test	P value
Total Bilirubin (mg/dl)	0.27 $\pm$ 0.04	1.09 $\pm$ 1.26	0.011
Direct bilirubin (mg/dl)	0.13 $\pm$ 0.03	0.44 $\pm$ 0.54	0.020
Indirect bulirubin (mg/dl)	0.16 $\pm$ .01	0.64 $\pm$ 0.82	0.020
SGOT ( IU/L )	21.01 $\pm$ 5.2	48.07 $\pm$ 32.69	.0002
SGPT ( IU/L )	16.07 $\pm$ 3.2	33.67 $\pm$ 18.82	0.001

Significant increase in bilirubin and hepatic enzymes levels was obtained in malaria male patients as compared to the controls (Table-3)

**Table-3: Comparison of serum total bilirubin and liver enzymes among male controls and male malaria patients**

Parameters	Controls	Test	P value
Total Bilirubin (mg/dl )	0.30 $\pm$ 0.03	1.67 $\pm$ 1.75	0.001
Direct bilirubin (mg/dl)	0.14 $\pm$ 0.02	0.53 $\pm$ 0.34	0.0001
Indirect bulirubin (mg/dl)	0.17 $\pm$ 0.01	1.18 $\pm$ 1.56	0.005
SGOT (IU/L)	22.56 $\pm$ 5.3	44.44 $\pm$ 30.88	0.002
SGPT (IU/L)	17.56 $\pm$ 3.04	37.21 $\pm$ 20.15	0.0001

Significant difference was not obtained in liver function parameters

**Table-4: Comparison of serum total bilirubin and liver enzymes among male and female malaria patients**

Parameters	male	female	P value
Total Bilirubin (mg/dl )	1.56 $\pm$ 1.72	1.09 $\pm$ 1.26	0.354
Direct bilirubin (mg/dl)	0.46 $\pm$ 0.21	0.46 $\pm$ 0.52	0.941
Indirect bulirubin (mg/dl)	1.12 $\pm$ 1.61	0.65 $\pm$ 0.82	0.267
SGOT ( IU/L )	48.38 $\pm$ 32.67	48.07 $\pm$ 32.69	0.974
SGPT ( IU/L )	37.53 $\pm$ 19.66	33.66 $\pm$ 18.82	0.502

Statistically significant positive correlation could not be established with liver enzymes and serum total bilirubin. (Table-5)

**Table-5: Pearson correlation coefficient among bilirubin and liver Enzymes**

Enzymes	Total Bilirubin	P Value
SGOT	0.015	0.463
SGPT	0.094	0.553

## Discussion

Investigations into the effects of Plasmodium parasites on the levels of serum enzymes have gained recognition as an important area of research in the pathogenesis of malaria. Malaria involves the liver where infective sporozoites invade and multiply in the hepatocytes and in the erythrocyte stage the merozoites cause the destruction of infected red blood cells.<sup>12</sup> Malyneux et al suggested that jaundice, which may be deep, is usually accompanied by only moderate elevation of hepatic enzymes and results more from

hemolysis than from hepatic damage.<sup>13</sup> The role of liver injury or hepatocellular damage in the malarial patients has been proposed by many workers especially in the Indian subcontinent. Raised serum bilirubin, hepatomegaly along with increase in liver enzymes are important denominator of liver injury in these patients.<sup>14</sup>

*P. vivax* was widely believed to be incapable of causing cytoadherence and microvascular sequestration as seen in *P. falciparum* infection and therefore unable to cause organ dysfunction. Recent observations have shown evidence of sequestration of parasite in lung vasculature during evaluation of lung injury in *p. vivax* malaria. Cerebral dysfunction of *P. vivax* malaria may occur through generation of nitric oxide.<sup>15</sup> cytokines and leukotrienes may be responsible for severe anemia and hemostatic complications. A few study clearly demonstrated that clinical severity of vivax malaria infection is strongly associated with potent activation of proinflammatory response and cytokines imbalance. Plasma tumor necrosis factor (TNF) which is related to *P. vivax* paroxysm was higher according to infection severity.<sup>16</sup> Interferon gamma (IFN) is also implicated in both resistance to malaria and disease immune pathology.

In our study, level of serum total bilirubin ranged from 0.31-7.33 mg/dl. Mean serum total bilirubin was significantly higher as compared to controls ( $p < 0.001$ ). Out of 64 malarial patients, 19.04% had increased serum total bilirubin level. Of these 75% patients had mild jaundice (2-5 mg/dl), 25% had moderate jaundice (5-10 mg/dl) and 0% had severe jaundice ( $> 10$ mg/dl). Our finding was in accordance with Kocher *et al* who showed that 70.6% of children suffering from malaria (*p. vivax*) had mild jaundice where moderate and severe jaundice was present in 23.5% and 5.9% of the children respectively.<sup>17</sup> Patwari *et al* observed jaundice in only 8.7% on *p. vivax* malarial cases.<sup>18</sup>

We observed statistically significant increase in levels of enzymes SGOT & SGPT in malarial patients ( $p < 0.001$ ) as compared to controls. These enzyme activities were also significantly higher in test males and test females as compared to their respective controls ( $p < 0.01$ ). But we could not find the significant difference in the mean enzyme activities in both male and female malarial patients ( $p > 0.05$ ). Our finding was supported by that of Jigam AA *et al*. According to them transaminases and ALP activities were significantly higher in patient groups but when compared ( $p < 0.05$ ).<sup>19</sup> Mohmad Ali *et al* showed increased activities

of SGOT, LDH, ALP and CPK in patients with *P. vivax* malaria where in cases of *P. falciparum* malaria, enzymes ALP, SGOT and CPK activities decreased and LDH activity increased significantly.<sup>1</sup> The increase in serum levels of hepatic enzymes; transaminases are the markers of liver damage. SGPT is a specific enzyme of liver. In this study we found that serum SGOT & SGPT levels were increased in 31% & 19% of the malarial patients. The mean level of AST was higher than that of ALT. It was similar to the findings of Kocher *et al*.<sup>17</sup> Study of Noppadon *et al* showed that AST levels were increased in 26% of *P. vivax* infection, 31% of *P. malariae* infection and 40% of *P. ovale* infection. Similarly, increased ALT levels was observed in 21% *P. vivax*, 30% *P. malariae* and 40% of *P. ovale* infections. ALP was increased in 20%, 22% and 20% of *P. vivax*, *malariae* and *ovale* infections respectively.<sup>20</sup>

Both the aminotransferases (AST & ALT) did not show statistically significant positive correlation with bilirubin ( $p > 0.05$ ) it signifies that rise in bilirubin from other sources like erythrocytes. Whereas other studies like Kauser MW *et al*, in their study obtained significant positive correlation of serum transaminases and ALP with serum bilirubin (2). Kocher *et al* also showed an excellent positive correlation of SGOT with bilirubin ( $p < 0.01$ ).<sup>17</sup>

## Conclusion

Malaria is a disease whose pathogenesis is not clearly defined as it is species-specific and of geographical variability. Thus the assessment of bilirubin and liver enzymes (like SGPT & SGOT) in malaria patients could represent additional and useful parameters in determining the clinical and prognostic aspects of the disease.

## References

1. Cox-Singh J, Davis TM, Lee, *et al*. Plasmodium Knowlesi malaria in human is widely distributed and potentially life threatening. *Clin infect dis*. 2008;46:165-71
2. World Health Organization. Communicable diseases. WHO Malaria facts and figures. World Health Organization, Europe. 2011.
3. I. Onyesom and N. Onyemakonor, Levels of

- Parasitaemia and Changes in Some Liver Enzymes among Malarial Infected Patients in Edo-Delta Region of Nigeria. *Current Research Journal of Biological Sciences* 2011; 3(2): 78-81.
4. Kumar A, Valecha N, Jain T and Dash AP. Burden of malaria in India: Retrospective and Prospective view. *Am. J Trop. Med. Hyg*; 2007; 77(suppl 6); pp 60-78.
  5. Trang TT, Phu NH, Vinh H, Hien TT, Cuong BM, Chau TT et al. Acute renal failure in patients with severe falciparum malaria. *Clin Inf Dis* 1992; 15: 874–80.
  6. Sina B. Focus on Plasmodium vivax. *Trends Parasitology* 2002;18:287-09
  7. Kausar MW, Moeed K, Asif A, Rizwi F and Raza S. Correlation of Bilirubin with Liver Enzymes in Patients of Falciparum Malaria. *International Journal of Pathology* 2010; 8(2): 63-67.
  8. Onyesom, I, Activities of some liver enzymes in serum of P. falciparum malarial infected humans receiving artemisinin and non-artemisinin-based combination therap. *Annals of Biological Research* 2012; 3 (7):3097-3100.
  9. C Burtis, E Ashwood, B Border: Liver functions. In: *Tietz Fundamentals of Clinical Chemistry, 5<sup>th</sup> (ed.)*, Saunders Company, Philadelphia, 2001; pp 748-770.
  10. Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in Pregnancy. *Lancet* 1999;354:546-09
  11. Agarwal AK chatterjee S. malaria. *API textbook of medicine, 10 edn*. Jaypee brothers medical publishers (P) Ltd; 2015. P.1612.
  12. Miller LH, Baruch DI, Marsh K and Doumbo OK et al. The pathogenic basis of malaria. *Nature* 2002; 415: 673-679.
  13. Molyneux ME, Looareesuwan S, Menzies IS and Grainger SL et al. Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. *Am J Trop Med Hyg* 1989; 4- (5):470-476.
  14. Kochar DK, Kaswan K, Kochar SK, Sirohi P, Pal M, Kochar A, et al. A comparative study of regression of jaundice in patients of malaria and acute viral hepatitis. *J Vect Borne Dis* 2006; pp. 123–129.
  15. Ozen M, Gungor S, Atambay M, et al. Cerebral malaria owing to Plasmodium vivax:case report. *Ann Trop Paediatr*. 2006;26:141-04.
  16. Karunaweera ND, Wijesekera SK, Wanasekera D, et al. the paroxysm of Plasmodium vivax malaria *Trends Parasitol*. 2003;19:188-93.
  17. Kochar DK, Tanwar GS, Khatri PC , Kochar SK, Sengar GS, Gupta A et al. Clinical Features of Children Hospitalized with Malaria—A Study from Bikaner, Northwest India. *Am. J. Trop. Med. Hyg*.I 2010; 83(5), pp. 981–989.
  18. Patwari A, Aneja S, Berry AM and Gosh S; Hepatic dysfunction in childhood malaria. *Archives of disease in childhood* 1979; 54, 139-141.
  19. Jigma AA and Niwoye AA; Assessment of some enzyme and haematological parameters in malaria patients resident in Minna; *IJBPAS* 2013; 2(1): 125-137.
  20. Tangpukdee N, Thanachartwe V, Krudood S, Luplertlop N, Pornpininworakij K, Chalermrut K et al. Minor liver dysfunctions in Plasmodium vivax, P. malariae and P. ovale patients and normalisation after treatment. *Korean journal of parasitology* 2006; vol 44, no 4, 295-302.